Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Revenue (2016 - 2025)

Lineage Cell Therapeutics' Revenue history spans 16 years, with the latest figure at $6.6 million for Q4 2025.

  • For Q4 2025, Revenue rose 130.4% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $14.6 million, up 53.24%, while the annual FY2025 figure was $14.6 million, 53.24% up from the prior year.
  • Revenue reached $6.6 million in Q4 2025 per LCTX's latest filing, up from $3.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $50.0 million in Q4 2021 to a low of $391000.0 in Q1 2021.
  • Average Revenue over 5 years is $5.0 million, with a median of $2.6 million recorded in 2023.
  • Peak YoY movement for Revenue: skyrocketed 13984.51% in 2021, then plummeted 96.17% in 2022.
  • A 5-year view of Revenue shows it stood at $50.0 million in 2021, then tumbled by 96.17% to $1.9 million in 2022, then grew by 9.03% to $2.1 million in 2023, then skyrocketed by 37.36% to $2.9 million in 2024, then surged by 130.4% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Revenue are $6.6 million (Q4 2025), $3.7 million (Q3 2025), and $2.8 million (Q2 2025).